Advertisement
Advertisement
U.S. markets close in 55 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Avadel Pharmaceuticals plc (AVDL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.85-0.29 (-4.06%)
As of 03:03PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close7.14
Open7.30
Bid6.79 x 1000
Ask6.81 x 800
Day's Range6.58 - 7.33
52 Week Range1.05 - 11.59
Volume698,009
Avg. Volume4,087,914
Market Cap409.585M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.54
Earnings DateAug 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.95
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AVDL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Avadel Pharmaceuticals plc
    Analyst Report: Jazz Pharmaceuticals plcJazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
    Rating
    Fair Value
    Economic Moat
    29 days agoMorningstar
View more
Advertisement
Advertisement